AstraZeneca's Breast-Cancer Trial Disappointment Doesn't Surprise — Market Talk

AstraZeneca's new breast-cancer drug Etcamah failed a late-stage clinical trial, but this was largely anticipated and might trigger a muted market reaction, J.P. Morgan analysts say in a research note. While disappointing, the study results from the U.K. drugmaker don't come as a big surprise after…